MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    A case of donepezil-induced multifocal myoclonus

    C. Amlang, P. Kim, A. Padalia, B. Roy, S. Schaefer (New Haven, CT, USA)

    Objective: To describe the case of a patient who developed severe multifocal myoclonus due to donepezil. Background: Donepezil is a cholinesterase inhibitor frequently used to…
  • 2019 International Congress

    A Case of Pregabalin induced Parkinsonism

    BC. Ari, F. Mayda Domac, G. Ozgen Kenangil (Istanbul, Turkey)

    Objective: Present a case of parkinsonism after administration of pregabalin, a rare case Background: Drug induced parkinsonism is the second common movement disorders after Parkinson’s…
  • 2019 International Congress

    Clinically Relevant Changes in AIMS Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated with Deutetrabenazine

    H. Barkay, A. Wilhelm, M. Wieman, M. Gordon, R. Hauser, JM. Savola (Netanya, Israel)

    Objective: To assess clinically relevant reductions with treatment of deutetrabenazine in abnormal involuntary movements in patients with tardive dyskinesia (TD), as evidenced by correlation between…
  • 2019 International Congress

    Toning down SPNs to improve motor responses to dopaminergic stimulation in Parkinson’s disease

    G. Beck, H. Mochizuki, S. Papa (Atlanta, GA, USA)

    Objective: This study was aimed at examining whether decreasing the baseline SPN firing frequency towards the low activity found in normal conditions reduces LID. Background:…
  • 2019 International Congress

    Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine

    S. Factor, C. Comella, S. Marder, J. Burke, K. Farahmand, S. Siegert (Atlanta, GA, USA)

    Objective: To assess the long-term outcomes of once-daily valbenazine (VBZ) on tardive dyskinesia (TD) using a formal assessment (Abnormal Involuntary Movement Scale [AIMS]) in participants…
  • 2019 International Congress

    Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study

    R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, M. Gordon, JM. Savola, K. Anderson (Tampa, FL, USA)

    Objective: To evaluate long-term efficacy of deutetrabenazine in patients with tardive dyskinesia (TD) by examining the change from baseline in Abnormal Involuntary Movement Scale (AIMS)…
  • 2019 International Congress

    Memantine induced dyskinesia in Alzheimer’s disease

    M. Kaiserova, L. Hvizdošova, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

    Objective: There is only little evidence for memantine induced dyskinesia in Alzheimer’s disease. We present a patient with Alzheimer’s disease who developed choreatic dyskinesia as a result…
  • 2019 International Congress

    Brain neurotransmitters and neuropeptides alternations in Parkinson’s induced mouse models

    N. Kumar, R. Khanna (Jaipur, India)

    Objective: Present study aimed to investigate the changes in brain neurotransmitters and neuropetides in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models  of PD. Background: Parkinson’s disease (PD), a…
  • 2019 International Congress

    Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers

    C. Kutz (Colorado Springs, CO, USA)

    Objective: To elicit and compare the treatment goals of patients with tardive dyskinesia (TD), their care partners, and healthcare providers (HCP). Background: Tardive dyskinesia (TD)…
  • 2019 International Congress

    Regardless of impaired renal function, negative myoclonus can be induced by gabapetin and pregabalin

    DY. Kwon, MH. Park (Gyenggi-Do, Republic of Korea)

    Objective: This study evaluated pregabalin- or gabapentin-induced negative myoclonus according to renal function. Background: Gabapentin and pregabalin are commonly used to control neuropathic pain and epilepsy.…
  • « Previous Page
  • 1
  • …
  • 1129
  • 1130
  • 1131
  • 1132
  • 1133
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley